Download O A RIGINAL

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Pharmacogenomics wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Pharmaceutical industry wikipedia , lookup

Prescription costs wikipedia , lookup

Pharmacognosy wikipedia , lookup

Psychopharmacology wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Neuropharmacology wikipedia , lookup

Drug interaction wikipedia , lookup

List of comic book drugs wikipedia , lookup

Bilastine wikipedia , lookup

Azathioprine wikipedia , lookup

Transcript
2835
Advances in Environmental Biology, 6(11): 2835-2840, 2012
ISSN 1995-0756
This is a refereed journal and all articles are professionally screened and reviewed
ORIGINAL ARTICLE
Study of Azathioprine Effects on Serum Markers of Insulin Resistance in Male Rats
1
Abbas Houshmandi, Farangis Ghassemi, Rouhollah Ardeshiri, Marzie Eilani
1
2
Department of Biology, Islamic Azad University, Jahrom, Fars, Iran.
Young Researchers Club, Islamic Azad University,Jahrom Branch, Jahrom, Iran.
Abbas Houshmandi, Farangis Ghassemi, Rouhollah Ardeshiri, Marzie Eilani; Study of Azathioprine
Effects on Serum Markers of Insulin Resistance in Male Rats.
ABSTRACT
Background: Diabetes is the most common metabolic disease in humans, which can lead to kidney damage;
Azathioprine is widely used in the treatment of other autoimmune diseases, cancer, and organ transplantation. In
this study, the effect of azathioprine on renal tissue and serum markers of insulin resistance in rats were studied.
Methods: In this research, 56 adult male wistar mouse with 80 to 90 days old and weighing approximately 200
±20g were diveded in 8 groups with 7 members as follow: Control group (without sugar and drug dose), sham
(140cc froctose 10% as a daily feeding) and 1 to 4 experimental groups that in addition of 140cc froctose 10%
as a daily feeding, were injected [3.75, 7.5, 15 and 21] mg/kg/bw azathioprine both in single dose and
interaperitoneal at 96th day. 24 hours after drug administration, blood samples were taken from all groups. Its
serum separated for biochemical study. Using statistical software, SPSS [18], data were analyzed by One Way
ANOVA and Duncan test at the significant level of 0.01. Results: Results showed that serumic amounts of blood
glucose (FBS), alkalinphosphotase (ALP) and cholesterol (LDL) in all experimental groups has significant
difference than control group (p<0.01). Direct and total bilirubin, aspartate aminotransferase (AST), urea
nitrogen, creatinine and cholesterol (HDL) were increased in diabetic groups. In other hand,in all experimental
groups, total protein and triglyceride (TG) were decreased significantly and no change in malondialdehid
(MDA), albumin and alanine aminotransferase(ALT) levels were observed. Conclusion: According to above
results, azathioprinein in diabetic patients spatially in high dose, cause liver damage and using this drug should
be restricted.
Key words: diabetes, azathioprine, kidney.
Introduction
In developing countries, one of the major
problems in diabetic nephropathy and progressive
renal failure is the end [16] that lead to dialysis and
eventually a kidney transplant disease mortality [13]
that such symptoms can be these include: increasing
the thickness of the glomerular basement membrane,
the rise and spread of renal interstitial tissues and
Increasing in creatinine, level. Our current
knowledge is limited about diabetic nephropathy.
However, the studies that have been done in this
area, have found that factors such as glycemic
control, blood pressure and improve kidney function
in diabetic nephropathy will eventually recover [1].
Glycosylation and lipid peroxidation leading to
increased oxidative stress due to excessive
production of reactive oxygen species (ROS) and
decreased antioxidant system is [8, 16]. Increased
production of free radicals cause lipid peroxidation
and damage to cell membranes, proteins and nucleic
acids and tissue damage by oxidation, resulting in
decreased glomerular filtration and renal damage
[16]. Azathioprine is immune suppressive drugs to
treat diseases such as leukemia; acute lymphoblastic,
inflammatory bowel disease and rheumatoid arthritis
are used. Azathioprine with corticosteroids, the best
option is to prevent organ rejection [3]. Drug
Azathioprine is a drug that can inhibit the synthesis
of purine bases and prevent re-replication in cells
that do not synthesize DNA and RNA through the
action takes place. Toxicity caused by the use of
these drugs has been demonstrated in organs such as
bone marrow, liver and gastrointestinal tract and
pancreas. Cytotoxic effect of the drug on the
production of free radicals in the body and organs of
the patient [14]. Many disorders, including
hypertension, insulin resistance, elevated blood lipids
and renal dysfunction is associated with diabetes,
metabolism and excretion of drugs and other toxic
changes [15]. Therefore the aim of this project
examined the effects of some factors on kidney
function azathioprine in mice resistant to insulin.
Materials and Methods
Corresponding Author
Abbas Houshmandi, Department of Biology, Islamic Azad University, Jahrom, Fars, Iran.
2836
Adv. Environ. Biol., 6(11): 2835-2840, 2012
In this study, 56 male Wistar rats weighing 200
± 20gr selected standard conditions (12 h light and
12 h dark and the temperature of 2 ± 22 ° C and
humidity of 55-50 percent) were maintained. To
create insulin resistance, mice were treated for 98
days with fructose (10%) were orally administered a
solution of water and were divided into eight groups
as follows:
Control group: no treatment control group
(diabetic) daily cc 140 solution of fructose (10%)
received group 1 to 4 (treatment of diabetes) after
receiving the oral solution of fructose (10%) for 98
days, respectively, kg / bw mg / (3/5, 5/7, 15 and 21)
received intra-peritoneal injection drug azathioprine.
Groups 5 and 6 (non‐diabetic treatment): day 98,
respectively (mg / kg 15 and 21) received intraperitoneal injection azathioprine. 24 hours after
injection, the animals were anesthetized by ether and
blood from the heart. Blood samples were
centrifuged for 10 minutes at a speed of 2500 rpm,
and serum was separated. Biochemical factors, uric
acid, albumin, protein, triglycerides, cholesterol,
creatinine, total protein, glucose (FBS), total
bilirubin (BT), direct bilirubin (BD) and urea
nitrogen (Bun) was measured using specific kits (6). Mean values obtained analyzed by statistical
software SPSS-18 and using (ANOVA) and Duncan
test for com[aring groups (05/0 ≤ P). The results
were presented as Mean ± SEM.
Results:
The results show that the mean serum uric
acid(fig 4), BUN(fig 2) and creatinine(fig3) in
diabetic treated and control groups (as diabetes
showed a significant increase. However, no
differences were observed in non-diabetic treatment
groups (05/0 <P) in the control group, mean serum
urea nitrogenor BUN (as diabetes) shows a
significant increase compared to the control group
and groups that have received only azathioprine(fig
1) (05/0 ≤ P). In all treatment groups, including
diabetic and non-diabetic serum LDL(fig 9) and
fasting glucose(fig 10) compared with the control
group (05/0 ≤ P) shows the concentration of HDL in
sham group and some diabetic groups treated,
decrease but the non-diabetic treatments didn't
chenge significantly and increased compared to the
diabetic groups.(fig 8). Albumin(fig 5) and
malondialdehyde(fig3) did not change significantly
(Table 1). Serum triglycerides (fig 7), total bilirubin
(fig11) significantly increased in diabetic treated
group (05/0 ≤ P) and total protein(fig 6), levels in
the treated diabetic group some treatments are nonsignificant decrease compared to controls.
Table 1: Comparison of biochemical parameters studied groups.
Comparison of various biochemical parameters
Witness
Azathioprine 15
Azathioprine 5/7
Azathioprine
+ DM
+ DM
75/3
+ DM
cd54/26±0/505
d96/5±25/593
ab44/49±0/167
ab85/78±6/211
ab15/20±0/210
b39/62±6/294
c89/40±18/108
a12/44±5/235
a35/30±75/374
a6/14±6/252
a64/48±6/389
a23/57±4/324
a27/88±8/342
a85/30±85/332
bcd25/1±5/13
cd03/1±25/14
bcd15/1±57/13
abcd649/0±42/12
abc649/0±57/11
ab21/1±57/10
a42/0±71/9
a129/0±3/3
a086/0±35/3
a04/0±38/3
a045/0±38/3
a08/0±32/3
a101/0±32/3
a075/0±24/3
a329/0±2/7
a108/0±2/7
ab163/0±6/7
ab121/0±55/7
ab165/0±37/7
a187/0±24/7
a354/0±84/6
a01/0±09/0
a01/0±08/0
b013/0±267/0
b015/0±288/0
b009/0±278/0
b021/0±29/0
b01/0±292/0
a029/0±287/0
a043/0±27/0
b016/0±681/0
b017/0±692/0
b007/0±691/0
b028/0±738/0
b013/0±708/0
a88/2±0/40
a19/4±25/41
bc31/6±14/72
ab69/2±57/52
bc12/5±14/67
bc36/4±14/73
cd2/10±57/82
d33/7±75/83
bc43/4±0/66
ab11/2±71/52
c88/3±57/68
abc69/2±85/60
abc03/4±57/56
a91/3±42/51
ab028/0±95/1
ab028/0±85/1
b02/0±99/2
b02/0±80/2
b028/0±71/2
b035/0±52/2
b04/0±49/2
c04/2±0/29
ac77/1±0/27
d52/1±28/45
db12/1±71/43
b25/1±42/40
b08/1±71/38
b65/0±21/38
a776/0±47/1
a242/0±07/1
b216/0±45/3
b529/0±52/3
b387/0±5/3
b397/0±41/3
b226/0±85/2
b9/14±25/114
c6/20±75/153
b67/3±0/111
b45/1±28/113
ab94/2±71/109
ab68/2±42/109
b0/2±0/120
Means in each row having at least one common letter are significantly different at the 5% level are Duncan test (05/0 ≤ P).
1-Control 2-sham 3- diabet+AZA(3.75) 4- diabet+AZA(7.5) 5- diabet+AZA(15) 6- diabet+AZA(21) 7- AZA(15) 8- AZA(21).
Azathioprine 21
Azathioprine 15
Fig. 1: bun level in serum.
Azathioprine 21
+ DM
Control
Group
a04/8±0/122
a88/23±2/303
d96/1±6/15
a083/0±4/3
b323/0±04/8
a01/0±076/0
a041/0±218/0
d17/12±2/97
abc93/5±6/56
a04/0±02/1
a44/0±55/25
a146/0±28/1
a61/2±6/90
Parameter
Protein
Malon
HDL
Albumin
TotalProtein
BD
BT
TG
Chol
Creat
Bun
UricAcid
FBS
2837
Adv. Environ. Biol., 6(11): 2835-2840, 2012
Fig. 2: creatinine level in serum.
Fig. 3: Malondialdehyde level in tissue.
Fig. 4: Uricacid level in serum.
Fig. 5: Albomin level in serum.
2838
Adv. Environ. Biol., 6(11): 2835-2840, 2012
Fig. 6: Totel prote levein serum.
Fig. 7: Triglycerid level in serum.
Fig. 8: HDL colesterol level in serum.
Fig. 9: LDL colestrol level in serum.
2839
Adv. Environ. Biol., 6(11): 2835-2840, 2012
Fig. 10: FBS level in serum.
Fig. 11: Bilirubin level in serum.
Discussion:
Diabetes is the most common endocrine
diseases, metabolic disorders can be applied to this
disease. In hyperglycemia, most cells cannot use
glucose for nutrition [10]. Evidence indicates that
hyperglycemia is an important factor for kidney
damage. Increased levels of uric acid, BUN,
creatinin, indicating kidney damage in diabetic [10]
into the tubular secretion of creatinine and
glomerular filtration on urine. Some drugs can
despite normal kidney function, decreased tubular
secretion may increase serum creatinine [14]. In
addition to drugs, other substances such as glucose,
uric acid, ketones and bilirubin levels can also cause
a sharp rise in serum creatinine are false changes
[14]. Ammonia from the amino acid is converted to
urea in the liver by a cyclic mechanism and inner
medullary nephron reabsorption in the urinecollecting tubes. Increased urea and uric acid in the
control group (diabetic) can be related to the
metabolism of the drug in the liver. The impact of
drug-induced damage to the liver may be a natural
cycle and its effects on some materials just does not
2840
Adv. Environ. Biol., 6(11): 2835-2840, 2012
happen all come together. If amino acids are
produced in the liver converts ammonia to urea in the
blood that cannot be moved. Ammonia is highly
toxic and can cause damage to the kidney tissue [14].
MDA as a specialized test known to show cause
oxidative damage [21] and the studies, blood glucose
and lipid peroxidation Glicolization due to changes
in the structure of proteins and lipids, and oxidative
stress would result in the creation of this lesion and
subsequent
diabetes
increased
levels
of
malondialdehyde [17]. The short duration of diabetes
research opportunities for Oxidative damage in mice
did not develop type II diabetes, especially the longterm effect, On the other hand, according to some
studies, after taking some poison [7], or drugs such
as azathioprine [3], MDA in blood or tissue, is
increased [18]. Diabetes is an indicator of kidney
damage. Azathioprine metabolism purine antagonist
and perhaps create free radicals, which inhibit the
synthesis of nucleic acids and proteins, and lipids [4]. Changing some parameters, such as increased total
bilirubin and direct, cholesterol, LDL and HDL in
the treatment of diabetic control, consistent with the
findings of others [3,2], mostly due to complications
from diabetes due to insulin resistance, cholesterol
metabolism and lipid is disrupted [19]. Increase in
fasting glucose in diabetic treatments induced
resistance in skeletal muscle, liver and adipose tissue
to insulin leading to reduced glucose uptake
(increased glucose), and increased hepatic glucose
production is Lipogensis [19]. Also the influence of
drugs on the synthesis of insulin receptors in cells
can be elevated fasting glucose [4].
4.
5.
6.
7.
8.
9.
10.
11.
Conclusions:
12.
According to the biochemical results,
azathioprine at doses used in this study did not cause
significant adverse effects except in diabetic patients
due to synergistic effects aggravate the damage.
Therefore, in such cases the drug has limitations.
13.
References
14.
1.
2.
3.
Ahmad, MS., N. Ahmed, 2006. Antiglycation
properties of aged garlic extract: possible role in
prevention of diabetic complications. J Nutr.,
136(3Suppl): 796S-9S.
Amin, A., AA. Hamza, 2005. Hepatoprotective
effects of Hibiscus, Rosmarinus and Salvia on
azathioprineinduced toxicity in rats. Life Sci.,
77(3): 266-78.
Amouoghli Tabrizi, B., D. Mohajeri, Y. Doostar,
S. Baradaran Alizade, A. Khodadadi and F.
Farajzade Biochemical and pathological study of
protective effect of Vitamin A in Azathioprineinduced hepatotoxicity in Rat, Feyz, Jouranal of
Kashan University of Medical Sciences. 2009;
13: 180-187.
15.
16.
Aninat, C., A. Piton, D. Glaise, T. Le
Charpentier, S. Langouet, F. Morel, C. GuguenGuillouzo, et al., 2006. Expression of
cytochromes P450, conjugating enzymes and
nuclear receptors in human hepatoma HepaRG
cells. Drug Metab. Dispos., 34: 75-83.
Burtis, CA., ER. Ashwood, 2000. Tietz
Fundamentals of Clinical Chemistry, 4th edn.
W.B. Saunders, Philadelpia, pp: 416-499, 574805.
Ceyhun, S., M. Şentürk, O. Ekinci and A. Çiltaş,
2010. Deltamethrin attenuates antioxidant
defense system and induces the expression of
heat shock protein 70 in rainbow trout
Comparative Biochemistry and Physiology Part
C: Toxicol & Phaol., //2% ( 152 (2): 215-223.
Kaneto, H., N. Katakami, D. Kawamori, et al.,
2007. Involvement of oxidative stress in the
pathogenesis of diabetes. Antioxide Redox
Signal, 9(3): 355-66.
Kang, KS., HY. Kim, JS. Pyo, T. Yokozawa,
2006. Increase in the free radical scavenging
activity of ginseng by heat-processing. Biol
Pharm Bull., 29(4): 750-4.
Kapoor, A., 2008. Malinnancy in kidney
transplant recipients. Drugs, 68: 11-19.
Memisogullari, R., S. Taysi, E. Bakan, I.
Capoglu, 2003. Antioxidant status and lipid
peroxidation in type II diabetes mellitus. Cell
Biochem Funct., 21(3): 291-6.
Murakami, T., R. Yumoto and M nk. Takano,
2003. Differential Effect of Acute Hepatic
Failure on in Vivo and in Vitro P-Glycoprotein
Functions in the Intestine, -Pharmaceutical
Research., 5(20): 765-771.
Park, S.W., S.M. Lee, 2008. Antioxidant and
prooxidant properties of ascorbic acid on renal
dysfunction
induced
by
cold
ischemia/reperfusion. Eur J Pharmacol., 580(3):
401-6.
Rainer, L., ED. Schleicher, 2000. Molecular
mechanism of diabetic nephropathy. Clinica
Chimica Acta 297: 135-44.
Raza, M., M. Ahmad, A. Gado, OA. AlShabanah,
2003.
A
comparison
of
hepatoprotective activities of aminoguanidine
and N-acetylcysteine in rat against the toxic
damage induced by azathioprine. Comp
Biochem Physiol C Toxicol Pharmacol, 134(4):
451-6.
Thomson, M., ZM. Al-Amin, KK. Al-Qattan,
LH. Shaban, A. Muslim, 2007. Anti-diabetic and
Hypolipidemic properties of garlic (Allium
sativum) in streptozotocin-induced diabetic rats.
Int J Diabetes & Metabolism, 15: 108-15.
Wu, YG., H. Lin, XM. Qi, GZ. Wu, H. Qian, M.
Zhao, et al., 2006. Prevention of early renal
injury by mycophenolate mofetil and its
mechanism in experimental diabetes. Int
Immunopharmacol, 445-53.